Index

ABC study, emotional and personality dysfunctions, 284
abstract language disturbance, prodrome basic symptoms, 99
abuse, depression, 288
access problems, treatment delays, 165–6
acoustic perception disturbances, prodrome basic symptoms, 100
Active Cognitive Therapy for Early Psychosis (ACE) study, 205
acute psychotic phase, emotional and personality
dysfunctions, 285–6
acute risk containment, suicide prevention, 272–3
adherence
  bipolar disorder treatment, 228–9, 235
  see also medication adherence/non-adherence
admission  see inpatient admission
adolescence
  CNS changes, 61
  emotional and personality dysfunctions, 284
adoption studies, environmental risk factors, 49
affective-dynamic disturbances, SPI-A, 91
affective psychosis
  atypical antipsychotic 191
  pharmacotherapy, 186, 191, 192
age, FEP, substance misuse, 244
age of onset, bipolar disorders, 233
AKT1 gene/protein, 32
Alcohol, Smoking and Substance Involvement Screening
  Test (ASSIST), 250
alcohol use
  bipolar disorder, 234
  suicide risk, 266
Alcohol Use Disorders Identification Test (AUDIT), 250
allele association studies, 34
  single nucleotide polymorphisms, 34
ambiguity, in diagnosis, 19
ambiguous loss, 315
Amish study, bipolar disorder prodrome identification, 232
amisulpride, 194
incomplete recovery therapy, 215
treatment-resistant major depressive disorder, 375
amphetamine use, psychosis relapse, 354
amygdala, structural neuroimaging, 69
anger/irritability, at-risk mental state, 114
anterior cingulate cortex, structural neuroimaging, 70,
antidepressant medication
bipolar disorders, 225
suicidal behaviour treatment, 273
treatment-resistant bipolar depression, 374
antipsychotic medication
adverse effects, 110, 187, 193–6
diabetes, 188–9, 195
endocrine effects, 189, 195–6
extrapyramidal motor symptoms, 188, 194–5, 228
metabolic effects, 193
metabolic syndrome, 188–9, 195
obesity, 188, 195
sexual side effects, 189, 195–6
extrapyramidal motor symptoms, 188, 194–5, 228
weight gain, 188, 195
atypical 194
affective psychosis, 191
maintenance therapy, 352
non-affective psychosis, 189
suicidal behaviour treatment, 273
treatment-resistant bipolar depression, 374
treatment-resistant bipolar mania, 374
bipolar disorder, 227, 228, 233
borderline personality disorder, 294
combination therapy, 375
DUP offset, 126
first-generation, 213
low-dose, FEP, 187, 193
monotherapy, 375
professionals, beliefs about, 151
public, beliefs about, 150, 151
relapse prevention, 356–7
response studies, 378
second-generation, 214
incomplete recovery therapy, 215
treatment-resistant schizophrenia, 371
treatment-resistant major depressive disorder, 375,
treatment-resistant schizophrenia, 371,
unacceptability to service users, 111
anxiety
at-risk mental state, 94, 114
incomplete recovery, FEP, 208
perseveratory delusions, 287
aripiprazole, 194
treatment-resistant major depressive disorder, 375
assertive community treatment team, FEP, 401
assessment phases, relapse prevention, 359
Association of Cognitive Analytic Therapy, 297
at-risk mental state, 7, 83–105
common problems, 114
hypothalamic–pituitary–adrenal axis, 96–7
cortisol, 96
identification, 85–93
basic symptoms criteria, 88–92
false positives, 85
rationale, 84–5
referral source effects, 88
see also specific methods
‘madness’ concerns, 111
management see at-risk mental state management
neurobiological variables, 96–7
gyrification index, 97
hippocampus, 96
pituitary gland, 97
reduced grey matter, 97
neurocognitive changes, 84
neurocognitive variables, 95–6
predictors, 93–7
psychopathological variables, 93–5
anxiety, 94
basic symptoms, 94
depression, 94
distress, 94
negative symptoms, 93–4
poor functioning, 94–5
positive psychotic phenomena, 93
schizotypal personality features, 93
stress, 95
substance use, 95
signs and symptoms, 107
see also prodrome, UHR
at-risk mental state management, 114, 165
antipsychotic medication, 108–11
evidence against, 110–11
support of, 108–10
see also specific studies
criteria, 107
ethics, 108
interventions, 108–15
see also specific interventions
monitoring, 113
no interventions, 113
psychoeducation, 118
psychological interventions, 111–13
  evidence against, 112–13,
  support of, 111–12
  see also specific studies
retrospective studies, 107
social interventions, 113
attentional defects, neuropsychological studies, 65
attention captivation, prodrome basic symptoms, 99
attention division inability, prodrome basic symptoms, 99
Attenuated Psychotic Symptoms (APS) Group, UHR criteria, 86
attenuated symptoms, prodrome, 83
attributions, family interventions, 322
atypical antipsychotic drugs, see antipsychotic medication,
atypical auditory P50 inhibition deficits, psychophysiological
  studies, 66
basic symptoms
  at-risk mental state, 88–92, 94
  prodrome, 83, 98–100
  behavioural disturbances, FEP, 178–9
  benzodiazepines, psychiatric emergencies, 193
  bilateral cingulate grey matter, neuroimaging, 70
  biological markers, 62–3
  diagnosis (of early psychosis), 19
  family history, see family history of psychosis
  see also endophenotypes
bipolar affective disorder, neuroimaging, 68
bipolar depression, 230
  identification, 232, 233
  pharmacotherapy, 191
  treatment resistance, 374–5,
bipolar disorders, 10–11, 223–39
  case studies, 226–7, 229
  Clinical Global Impressions (CGI) score, 234
  comorbidities, 234
  depression, see bipolar depression
  early intervention, 223–5
  outcome, 224,
  psychotic disorders vs., 225
  targets, 229–30
  first-episode mania, 230
  comorbidities, 230
  identification of, 231–2, 233
  non-recognition of, 230
  functional recovery, 225
  identification
age of onset, 233
initial prodrome, 231–2
  manic episodes, 232
problems, 231, 233
initial prodrome, 230–1
psychological interventions, 234–5
  CBT, 234
  developmental issues, 234
  family input, 235
psychoeducation, 234
rapid cycling, see rapid cycling bipolar disorders
  recovery rates, 229
  relapse prevention, 235
  substance use, 225
symptomatic remission, 225
syndromal remission, 224
  treatment, 227–9, 233–4
  adherence, 228–9, 235
  antidepressants, 225
  antipsychotic medication, 227, 228, 233
  current guidelines, 227–8,
  current practice, 228
  delay 226
  delay, consequences of 226
  delay, factors 226
treatment resistance
  definition, 366
  non-pharmacological management, 376
  pharmacological treatment, 373
  prevalence, 367
  see also specific disorders
birth cohort studies, neuropsychological studies, 63
body perception disturbance, SPI-A, 91
borderline personality disorder, 12, 293–4
  antipsychotic medication, 294
  cognitive analytic therapy, 296
  co-occurring psychosis, 294
  therapeutic interventions, 295–7
Helping Young People Early Clinic, 297
psychotic symptoms, 294
brain-derived neurotrophic factor (neurotropin 3), 37–8
  C-270T polymorphism, 37
  functional neuroimaging, 40
  G196A polymorphism, 37
  linkage studies, 41
brief limited intermittent psychotic symptoms group, 86
Brief Psychiatric Rating Scale (BPRS), 86
relapse definitions, 350
C270T polymorphism, brain-derived neurotrophic factor, 37
Calgary Early Psychosis Treatment Service see CEPTS
cannabis use
  COMT gene, 54–5, 246
  FEP, 243, 246, 247
  psychosis relapse, 354
cardiovascular disease, FEP, 184
care pathways, 397
care provision, EPPIC, 386
carer–patient contact, expressed emotion, 306
case examples
  emotional and personality dysfunctions, 295
  relapse prevention, 359,
case management, 396
Case Management Manual, EPPIC, 386
case studies
  at-risk mental state management, 116–17
  bipolar disorders, 226–7, 229
  treatment resistance, 377–7
catechol-O-methyltransferase see COMT
CBT (cognitive–behavioural therapy)
Active Cognitive Therapy for Early Psychosis study, 205
  at-risk mental state management, 112
  bipolar disorders, 234
CEPTS, 396
definition, 292
  early-recovery phase, 205–6, 212
  emotional/personality dysfunction, 291–3
  FEP, substance misuse, 248, 252–3
LEO Service, 390
Norfolk Early Intervention Service programme, 344
PRIME study, 115
relapse prevention, 357, 360
staging model, 24
treatment-resistance schizophrenia, 375
central nervous system (CNS), adolescence, changes in, 61
CEPTS (Calgary Early Psychosis Treatment Service) 207, 395–8
care pathways, 397
case management, 396
CBT, 396
  characteristics, 396
  components, 396
effectiveness research, 397–8
  family, impact on, 397
  family interventions, 396
  group programme, 396
  medication adherence, 397
  performance measurement, 398,
  programme evaluation, 396–8
psychiatric management, 396
  substance abuse, 397
children
  emotional and personality dysfunctions, 284
see also adolescence
CHRNA7 (nicotinic acid receptor) gene/protein, 32, 38
chronosomal translocations, schizophrenia, 36
chronic illness see illnesses, chronic
Clinical Global Impression Severity (CGI-S) Score, 189
  relapse definitions, 350
clinical judgement, diagnosis (of early psychosis), 19
Clinical Practice Improvement Network for Early Psychosis, EPPIC, 389
clinical studies, psychological variables in relapse, 354
clinician errors, treatment delays, 171
clozapine, 194
  FEP, 214
  incomplete recovery therapy, 215
  suicidal behaviour, 273
treatment-resistant bipolar mania, 374
treatment-resistant schizophrenia, 373
clubhouse model, 335–8
  Program of Assertive Community Treatment vs., 336
  studies in, 336–8,
supported employment vs., 338
  transitional employment, 335
 cognition, endophenotypes, 64
cognition activation tasks, functional neuroimaging, 67
cognitive analytic therapy, 295–7
  borderline personality disorder, 296
  Helping Young People Early Clinic, 297
  psychosis, 296–7
cognitive assessment, FEP, 184
Cognitive Assessment and Risk Evaluation (CARE) Clinic, 87
cognitive–attentional impediments, SPI-A, 91
cognitive–behavioural therapy, see CBT
cognitive impairment, 94
  at-risk mental state, 95
  COMT gene, 36
  FEP, 182
  incomplete recovery, 209
  relapse, 355–6
SPI-A, 91
cognitively oriented psychotherapy for early psychosis, 205
cognitive models, social anxiety, 290–1,
cognitive therapy
  Early Detection and Intervention Evaluation, 111
EPPIC, 340–1
UHR, 97

cohort characteristics, DUP follow-up studies, 133–6
Cologne Early Recognition and Intervention Centre for
Medical Crisis see FETZ (Früh-Erkennungs and
Therapie-Zentrum für psychische Krisen)
Cologne Early Recognition Study, 88–9
community campaigns, mental health literacy, 153–5
community efforts, treatment delay reduction, 168
community mental health literacy, 8
Community Treatment Orders, 276
comorbid disorders, see FEP assessment
comorbid psychiatric disorders, FEP, 188, 194–5
The Compass Strategy (Australia), 154–5, 156, 158
Comprehensive Assessment of At Risk Mental State (CAARMS)
Early Detection and Intervention Evaluation, 116
PACE UHR criteria, 86, 87
comprehensive treatment services, FEP, substance
misuse, 249
COMT (catechol-O-methyltransferase) gene, 32, 36
associated behaviour, 31
cannabis use, 54–5, 246
cognitive impairment, 36
as endophenotype, 38
functional neuroimaging, 67
manic-depressive illness, 36
Val158Met genotype, 36, 55
concentration/attention problems, at-risk mental state, 114
coping strategies, family interventions, 322–3
cortical folding patterns, structural neuroimaging studies, 68,
cortisol, hypothalamic–pituitary–adrenal axis, 96
counselling, public, beliefs about, 150
counsellors, public, beliefs about, 149
crisis assessment team, LEO, 389, 391,
Criteria for Prodromal Symptoms (COPS), PRIME study, 109
cultural factors, suicide risk factors, 267–8
cultures, expressed emotion, 306, 311
cytoskeleton, DISC1, 37
DAAO gene/protein, 32
DAOA gene/protein, 32, 35
NMDA receptor, 35
single nucleotide polymorphisms, 35
Dartmouth Assessment of Lifestyle Instrument (DALI), 250
data extraction, DUP follow-up studies, 132–3
debriefing, suicide prevention, 273
Delphi consensus technique
CEPTS, 398
relapse definitions, 350
delusions
at-risk mental state, 114
emotional and personality dysfunctions, 286–7
FEP, 182
persecutory
anxiety, 287
emotional and personality dysfunctions, 287
demography, treatment delay, 166–7
depression, 285–6
abuse, 288
at-risk mental state, 94, 114
bipolar disorders see bipolar depression
incomplete recovery, FEP, 208
postsychotic, 286
public recognition of, 148
suicidal behaviours, 261
derealization, prodrome basic symptoms, 99
Developmental Processes in Schizophrenic Disorders Project,
UCLA Aftercare Research Program, 342
diabetes, antipsychotic medication, 188–9, 195
diagnosis (of early psychosis), 17–27
aims of, 18
ambiguity, 19
biological markers, 19
clinical judgement, 19
crystallized disorders vs., 18–19, 134–5
non-specific symptoms, 19
timing difficulties, 19
validity, 18–20
DISC1 gene/protein, 32, 36–7, 72
cytoskeleton, 37
functional neuroimaging, 67
linkage studies, 41
discrimination decrease, prodrome basic symptoms, 99
disrupted in schizophrenia-1 gene/protein see DISC1 gene/
protein
distress, at-risk mental state, 94
distress level studies, family caregiving, 313, 314
DNA methylation, 50,
epigenetics, 39
dorsolateral hyperfrontality, functional neuroimaging, 67
DRD3 gene/protein, 38
DTNBP1, 32
linkage studies, 41
DUP (duration of untreated psychosis), 7–8, 125–45, 147
estimates, 161
follow-up studies, 129, 130–3
cohort characteristics, 133–6
data extraction, 132–3
measurement methods, 130–2
outcome types, 132
DUP (duration of untreated psychosis) (cont.)
premorbid adjustments, 136–8, 139
quantitative data analysis, 133
results, 133–9
see also specific results
search strategies, 130
sensitivity analysis, 138–9, 140–1
study characteristics, 18–19, 133, 134–5
study selection, 130
validity assessment, 132
Hillside study, 142
initial assessment, 180
lack of correlation, 142
minimization aims, 24
‘neurotoxic’ effects, 161
offset definition, 125–7,
onset definition, 125–7
consistency lack, 125
illness status, 127
retrospective data, 127
outcome effects, 129–30, 131, 136, 213
heterogeneity effects, 136
long-duration vs. short-duration groups, 136, 137, 138
participant numbers, 136
P300 abnormality, 66
patient vs. carer accounts, 127–8
professional contact to treatment delay, 161, 164–5
relapse effect, 356
retrospective assessment, 127
sample bias, 128
standardized assessment instruments, 128–9
Suffolk County study, 142
symptom to professional contact delay, 161
see also treatment delay reduction
duration of active psychosis, 213
duration of treated psychosis
definition, 127
negative outcomes, 127
duration of untreated illness, 180
duration of untreated prodromal psychosis, 180
duration of untreated psychosis see DUP
duration of untreated psychosis in treatment, 213
dysbindin, 34
functional neuroimaging, 67
dystrophin-associated protein complex (DPC), 34
Early Case Identification Program (Canada), 155
Early Detection and Intervention Evaluation, 111–12, 115–16
cognitive therapy, 111
Comprehensive Assessment of At Risk Mental State, 116
transition rates, 87
eye detection effects
bipolar disorders, 231–2
DUP outcome effects, 129
eye initial prodrome state
FETZ, 89, 90, 116
German Research Network on Schizophrenia, 89, 90
early intervention
eye initial intervention targets, bipolar disorders, 229–30
suicidal behaviour treatment, 275
Early Psychosis Intervention Program, 155, 169,
family intervention stage models, 320
success of, 170
Early Psychosis Prevention and Intervention Centre see EPPIC
eye psychosis service models, 14, 385–404
see also specific models
eyey recovery phase, 10, 201–14
pharmacology, 202–4
long-acting novel antipsychotic drugs, 203–4
poor efficacy, 203
poor tolerability, 203
relapse, 204
reviews, 203
switching treatment, 203
psychosocial treatments, 204–7
CRT, 204–6, 212
family therapy, 207
phase-specific group treatment, 206
psychoeducation, 204
recovery stage model, 207
vocational interventions, 206–7
see also specific clinical trials
eye early warning signs, relapse, 355
Early Warning Signs Scale, 355
ECT see electroconvulsive therapy
Edinburgh High-Risk Study (EHRs), 64
emotional and personality dysfunctions, 284
symptom severity, 64
education level, treatment delays, 166
electroconvulsive therapy
suicidal behaviour treatment, 273
treatment-resistant bipolar depression, 374
treatment-resistant bipolar mania, 374
treatment-resistant major depressive disorder, 376
emergency departments, inpatient admission, 165
emotional and personality dysfunctions, 12, 283–302
acute psychotic phase, 285–6
case example, 295
CBT, 291–3
historical aspects, 283–4
persecutory delusions, 287
prior to onset, 284
prodromal phase, 284–5
psychosis interactions, 286–8
adolescents vs. adults, 289
delusions/hallucinations, 286–7
diagnostic implications, 289
maintenance processes, 287–8
psychological reaction, 289–91
shame/stigma, 289–90
shared developmental pathways, 288–9, 290
social anxiety, 289–90
traumatic reactions, 289
psychosis link, 286–91
safety behaviours, 287
see also borderline personality disorder; specific dysfunctions
emotions, suicidal behaviours, 259
employment
barriers to work functioning
rates, 333
specialists, UCLA Aftercare Research Program, 342
Employment Intervention Demonstration Project, 336
endocrine effects, antipsychotic medication, 189, 195–6
endophenotypes, 6–7, 38–9, 61–80
characteristics, 61
chronic illness effects, 62
cognition, 64
deficits, 62
definition, 38
established disease effects, 61
event-related brain potentials, 62
executive functions, 71
family history see family history of psychosis
frontal lobe integrity, 71
functional neuroimaging see neuroimaging functional
general cognition, 63
GRM3 gene/protein, 39
markers of inhibitory control, 71
neuropathology, 61
neuropsychological studies see neuropsychological studies
neuropsychological test performance, 38
psychophysiological studies see psychophysiological studies
structural neuroimaging see neuroimaging, structural
study selection, 56
temporal effects, 62
working memory, 72
environmental risk factors, 5, 47–59,
adoption studies, 49
epidemiology, 49
family studies, 49
gene relations, 47–8
see also gene–environment correlation, gene–environment interactions
measurement of, 56
paternal age, 50, 53
psychometric psychosis liability, 49–50
schizophrenia, 40
twin studies, 49
epigenetics, 39
DNA methylation, 39
EPIP see Early Psychosis Intervention Program
EPPIC, 169, 385–9
depression, 225, 234
care provision, 386
Case Management Manual, 386
clinical guidelines, 386
Clinical Practice Improvement Network for Early Psychosis, 389
clinical subprogrammes, 386–7
cognitive therapy studies, 340–1
comprehensive service model, 389
continuing care team, 386
early recovery phase, 208
emotional and personality dysfunctions, 295
family/career programmes, 388
family interventions, 358
family work interventions, 386
funding constraints, 401
incomplete recovery treatment, 214,
inpatient care, 387–8
intensive care management team, 387, 388
Long Term Follow-Up Study 389
ORYGEN research centre, 388
preexisting cognitive problems, 387
psychosis incidence, 386
relapse prevention, 358
research and evaluation, 388–9
service model components, 386–8
suicidal behaviour, 261
suicide risk monitoring, 271
TREAT programme 387,
vocational interventions, 340–1
Youth Access Team, 386
youth participation, 388
ERBB4 gene/protein, 32
Index

ethics, at-risk mental state management, 108
ethnicity
LEO, 390
suicide prevalence, 267
treatment delays, 166
European Prediction of Psychosis Study, 91
event-related brain potentials, 62
executive functions, 71
expressed emotion (EE), 306–12
detection problems, 308–12
emotional overinvolvement vs., 311
level monitoring, 315
outcome effects, 308
loss reaction, 353
patient conflicts, 311
predictive validity, 306–7
relapse mechanisms, 307
relapse predictors/risk factors, 353
social context, 311
in UHR, 307–8, 309–10
expressive speech disturbance, prodrome basic
symptoms, 99
extrapyramidal motor symptoms, antipsychotic medication,
188, 194–5, 228
false positives
at-risk mental state identification, 85
prodrome, 92
families
bipolar disorders, 235
caregiving, 312–15
distress level studies, 313, 314
EPPIC, 388
experiences of, 312–15
illness duration effects, 313
individual differences, 315
loss and grief issues, 315
specific issues, 313
during course of psychosis, 305–12
emotion see expressed emotion
history of psychosis, 62
first-generation studies, 51, 52,
follow-up periods, 62
gene–environment interactions, 48, 51–3
twin studies, 49, 51
studies, 63
treatment delays, 168
LEO, 390
as psychotic cause, 305
recovery model, 316–20
segregation studies, 33
studies, environmental risk factors, 49
suicide risk factors, 267–8,
therapy
early recovery phase, 207
incomplete recovery therapy, 216
treatment, seeking of, 163, 170
family interventions, 13, 305–29
CEPTS, 396
components and guidelines, 320–1,
coping strategies, 322–3
FEP, 315–21,
substance misuse, 248
future work, 323–4
implementation, 323
psychoeducation, 322
attributions, 322
OPUS, 400
relapse prevention, 357–8
stage models, 316–20
supportive interventions, 321–2
treatment aims, 321
work interventions, EPPIC, 386
fear of psychosis, 112
FEP (first-episode psychosis) 9, 21, 23, 24
assessment see FEP assessment
cognitive dysfunction, 184
eyearly recovery phase see early recovery phase
dysfunction see early recovery phase
emotional/personality dysfunctions, 294
prevalence, 294–5
expressed emotion see expressed emotion
family interventions, 315–21,
incomplete recovery from see incomplete recovery, FEP
recovery from, 201
remission, 201
substance abuse see FEP substance abuse
suicide, 260
acute phase, 260–2,
treatment see FEP treatment
vocational interventions, 339–45
FEP assessment, 9–10, 177–200,
aims, 177–80
see also specific aims
behavioural disturbances, 178–9
biomedical evaluation, 184
clinical history, 180–2,
comorbid disorders, 181, 182–3
diagnostic evaluation, 185
 differential diagnosis, 186, 191
 initial contact planning, 178
 integrated treatment plan, 179–80
 mental state examination, 181, 182
 neuropsychological assessment, 184–5
 personal context recognition, 178
 personal history, 180–2,
 problems with, 177
 psychobiological assessments, 180–5
 psychosis recognition, 178
 recommendations, 184, 189–91
 remission, 181, 183–4
 social assessment, 181
 therapeutic alliance, 177–8
 FEP substance abuse, 243–5
 assessment feedback, 251
 cannabis, 243, 246, 247
 psychological interventions, 247
 correlates/consequences, 244–5
 engagement, 249
 information sources, 251
 initial assessment, 249–50,
 motivation to cease, 250–1
 persistence, 244
 prevalence, 243
 psychological interventions, 247–53,
 CBT, 248, 252–3
 comprehensive treatment services, 249
 established psychotic disorders, 247
 family interventions, 248
 harm minimization, 252,
 motivational interviewing, 248, 252
 psychoeducation, 251–2
 randomized controlled trials, 247,
 stepped care, 249
 types, 247
 rate and patterns, 243–4
 reasons for, 245–7
 common factors, 246–7
 personality traits, 246
 psychosis causes substance abuse, 245
 self-medication hypothesis, 245
 substance abuse causes
 psychosis, 245–6
 temporal order, 244
 tobacco, 243, 244
 psychological interventions, 248
 FEP treatment, 9–10, 177–200
 adherence to, 212–13
 impaired adherence therapy, 213–14
 outcome definitions, 201
 pharmacology, 185–9, 191
 changes in, 188–9, 195
 comorbid psychiatric disorders, 188, 194–5
 integrated treatment, 187
 low-dose antipsychotic drugs, 187, 193
 non-affective vs. affective psychosis, 184, 186, 187, 189–91, 192
 patient/relation input, 187
 principles, 185
 response, timing of, 181, 189
 treatment adherence, 188, 195
 treatment delay reduction, 185
 unfavourable outcome identification, 189, 195–6
 see also antipsychotic medication
 treatment resistance, 202, 214
 FETZ (Früh-Erkenntnus und Therapie-Zentrum für psychische
 Krisen), 89, 90, 116
 early initial prodrome state, 89, 90, 116
 Early Recognition Study 88–9
 late initial prodrome state, 89, 90, 116
 FEZ1 gene/protein, 32
 first aid skills, public knowledge/beliefs, 148–9
 first-episode bipolar psychosis services, FEPP, 394
 first-episode mania see bipolar disorders
 first-episode psychosis see FEP
 First Episode Psychosis Program, see FEPP
 FEEP (First Episode Psychosis Program), 392–5
 Assertive Community Treatment Team, 401
 First Episode Assessment and Care Team Clinic 387
 FACT–PEEL 394
 components, 392–5
 see also specific components
 early psychosis unit, 393
 family intervention stage models, 316–20
 FEP bipolar services, 394
 First Episode Psychosis Clinic, 387
 funding constraints, 401
 Home Intervention Program for Psychosis, 393
 inpatient service, 392–3
 Learning, Education, Advocacy and Recreation Network
 (LEARN) programme, 393, 394
 PRIME clinic, 392, 395
 referral criteria, 394–5
 research mandate, 395
 service pathways, 394–5
 services, 392
Index

first-generation antipsychotic drugs  see antipsychotic medication, first-generation
forensic history, FEP, 180
formal caregivers, expressed emotion, 307
frontal lobe integrity, endophenotypes, 71
fronto-striatal function, functional neuroimaging, 68
functional magnetic resonance imaging functional neuroimaging  see neuroimaging; functional 67
functional recovery, bipolar disorders, 225
functioning levels, treatment delays, 167
funding constraints
EPPIC, 401
FEPP, 401
LEO Service, 401
GAD1 (glutamic acid decarboxylase 1), 32
gender
expressed emotion, 306
FEP, substance misuse, 244
treatment delays, 166
gene–environment links 47–8
correlation (rGE), 47, 48
confounding, 56
evocative, 56
passive, 56
interactions, 40, 47, 48, 50
first-generation studies, 48, 51–3
migration designs, 49
rearing environment measures, 49
sample size, 56
second-generation studies, 54–5
see also endophenotypes
general cognition, endophenotypes, 63
general education development, Learning, Education, Advocacy and Recreation Network programme, 393
general population screening, prodrome, 92
general practitioners
inpatient admission, 165
primary help seeking, 163,
public, beliefs about, 149
genetics, 4–5, 31–46
allele association studies, 34
environment relations  see gene–environment link linkage studies, 33, 41
multiple tests, 57
structural neuroimaging, 70
suicide risk, 266
susceptibility genes, 31, 32
see also specific genes
genome-wide linkage studies, 33
eyearly initial prodrome state, 89, 90
late initial prodrome state, 89, 90
needs-focused intervention, 91
Global Assessment of Functioning (GAF) scale, PRIME study, 109
glutamic acid decarboxylase 1 see GAD1 (glutamic acid decarboxylase 1)
functional neuroimaging, 67
grey matter
density, structural neuroimaging studies, 68
reduced in at-risk mental state, 97
GRM3 gene/protein, 32
as endophenotype, 39
group programme, CEPTS, 396
group therapy, incomplete recovery therapy, 216
gyrification index, at-risk mental state, 97
hallucinations, triggering, emotional and personality dysfunctions, 288
haloperidol, maintenance medication, 357
harm minimization, FEP, substance misuse, 252,
health belief model, FEP treatment, 212
health professionals
knowledge/beliefs of, 151–3,
public knowledge/beliefs, 149, 150
Helping Young People Early Clinic borderline personality disorder, 297

cognitive analytic therapy, 297
heterogeneity effects, DUP outcome effects, 136
Hillside Recognition and Prevention Program
Criteria, 92
Clinical high-risk patients, 92
duration of untreated psychosis, 142
hippocampus
at-risk mental state, 96
structural neuroimaging, 69
Home Intervention Program for Psychosis, FEPP, 393
5HT2a gene/protein, 38
hyperprolactinaemia, antipsychotic drugs, 196
hypothalamic–pituitary–adrenal axis structural neuroimaging studies, 69
see at-risk mental state
ICD-10 schizophrenia diagnosis, OPUS, 398
identification (of psychosis), 7–8
see also diagnosis (of early psychosis)
 illicit drug use see substance abuse/misuse
illness duration effects, family caregiving, 313
illnesses, chronic
endophenotypes, 62
suicide risk, 286
illness status, onset, 127
impaired adherence therapy, FEP treatment, 213–14
imprinting, 50
incidence (of psychosis) see psychosis
incomplete recovery, FEP, 10, 201–14,
anxiety, 208
cognitive defects, 209
comorbidities, 211
depression, 208
negative symptoms, 208
ongoing positive symptoms, 208
outcome confounders, 209–13
pharmacotherapy, 215
positive symptoms, 215
psychological adjustments, 212
psychosocial therapy, 215–16
social deficits, 208–9
treatment approaches, 214–16
individual placement, vocational interventions, 338–9,
individual placement and support approach, 338–9, 340, 342–3
assessment of, 338–9,
CFT, 340
individual psychotherapy
FEP, incomplete recovery, 215–16
incomplete recovery therapy, 215–16
individual training programmes, mental health literacy, 157
industrial therapy, 334
information sources, FEP, substance misuse, 251
inhibitory control, endophenotypes, 71
initial contact planning, FEP, 178
initial prodrome, bipolar disorders see bipolar disorders
initial risk assessment, suicide prevention see suicide prevention
inpatient admission
emergency departments, 165
general practitioners, 165
professionals, beliefs about, 151
public, beliefs about, 150, 151
inpatient care
EPPIC, 387–8
FEP, 392–3
LEO Service, 389, 390–1
intensive care area, psychiatric emergencies, 193
intensive care management team, EPPIC, 387, 388
intermediate phenotypes see endophenotypes
International Center for Clubhouse Development, 335
International Early Psychosis Association
relapse prevention, 349
treatment guidelines, 117
interpersonal and social rhythm therapy,
treatment-resistant bipolar disorder, 376
interpersonal difficulties, at-risk mental state, 114,
Interview for the Retrospective Assessment of the Onset of Schizophrenia (IRAOS), DUP measurement, 130
Italy, social firms, 335
job agencies, vocational interventions, 341
Lambeth Early Onset Service see LEO Service
late initial prodrome state
FETZ, 89, 90, 116
German Research Network on Schizophrenia (GRNS), 89, 90
Learning, Education, Advocacy and Recreation Network (LEARN) programme see FEPP
LEO (Lambeth Early Onset Service), 389–92
CBT, 390
crisis assessment team (LEO CAT), 389, 391,
ethnic populations, 390
funding constraints, 401
historical context, 389–90
inpatient care, 389, 390–1
LEO Research and Coordination group, 391,
Outreach and Support in South London (OASIS), 389
outreach team, 389, 390
psychosis incidence, 389
Research and Coordination Group 391,
research and evaluation, 391–2
service model components, 390–1
see also specific components
life events, relapse predictors/risk factors, 354
LifeSPAN therapy, suicidal behaviour treatment, 274
linkage studies, 33, 41
brain-derived neurotrophic factor, 41
DISC1 gene/protein, 41
DTNBP1, 41
NRG1 gene/protein, 41
lithium, suicidal behaviour treatment, 273
Liverpool University Neuroleptic Side-Effect Rating Scale, 203
long-acting novel antipsychotics drugs, 203–4
longitudinal studies
neuropsychological studies, 65
psychophysiological studies, 66
structural neuroimaging studies, 69
Index

long-term studies, neuropsychological studies, 63
loss and grief issues, family caregiving, 315
‘madness’ concerns, at-risk mental state, 111
magnetic resonance spectroscopy, 69
maintenance therapy, 353
atypical antipsychotic drugs, 352
emotional and personality dysfunctions, 287–8
needs-adapted treatment model, 353
relapse prevention, 356
major depression, selective serotonin-reuptake inhibitors, 191
major depressive disorder, treatment resistance
definition, 366–7
non-pharmacological management, 376–7
pharmacological therapy, 374–5,
prevalence, 367–8
maladaptive beliefs, emotional and personality dysfunctions, 287
manic-depressive illness, COMT gene, 36
manic episodes, bipolar disorders, 232
markers of inhibitory control, endophenotypes, 71
medial temporal structures, structural neuroimaging, 69
medical disorders, FEP, 183
medication
LEO Service, 390
suicide prevention, 273
suicide risk, 267, 269
see also specific diseases/disorders; specific medications
medication adherence/non-adherence
CEPTS, 397
relapse predictors/risk factors, 352–3
medication discontinuance
OPUS, 399
relapse predictors/risk factors, 352, 356
Mental Health First Aid Course, 157,
mental health literacy, 147–60
definition, 147
historical improvements, 153
interventions, 153–8
community campaigns, 153–5
individual training programmes, 157
school-based programmes, 155–7
see also public knowledge/beliefs
mental health service provision models, suicide prevention, 275–6
Mental Illness Aware Week (USA), 155
Mental Illness Education (Australia), 114
mental state examination, see FEP assessment
metabolic syndrome, antipsychotic medication, 188–9, 195
migration designs, gene–environment interactions, 49
mismatch negativity, psychophysiological studies, 66
monitoring
at-risk mental state management, 113
psychiatric emergencies, 193
mood cycling, treatment resistance, 366
mood stabilizers
affective psychosis, 191
bipolar disorder, 227, 228
treatment-resistant bipolar depression, 374
treatment-resistant bipolar mania, 373
motivational interviewing, FEP, substance misuse, 248, 252
motivation problems, at-risk mental state, 114
MRDS1 gene/protein, 32
multifamily work, relapse prevention, 357
multiple family group treatment, OPUS, 400
mutations, 50
MUTED gene/protein, 32
N-acetylaspartate (NAA), 69
National Institute for Health and Clinical Excellence (NICE),
relapse-prevention treatment guidelines, 349
needs-adapted treatment model, maintenance medication, 353
negative symptoms, at-risk mental state, 93–4, 114
neocortical surface, structural neuroimaging, 71
Netherlands Mental Health Survey and Incidence Study, bipolar
disorder, 226
networks, suicide prevention, 268
neuregulin (NRG1), 32, 35
functional neuroimaging, 67,
linkage studies, 41
neuroanatomy, endophenotypes, 61
neurobiology, 5–6
prodrome, 84
see at-risk mental state
neurocognitive variables
at-risk mental state, 84
prodrome, 84
neurodevelopment
schizophrenia, 39
staging model, 20
neuroimaging
functional neuroimaging, 67–8
brain-derived neurotrophic factor, 40
cognition activation tasks, 67
COMT gene/protein, 67
DISC1, 67
dorsolateral hyperfrontality, 67
dysbindin, 67
fronto-striatal function, 68
GAD1, 67
neuregulin, 67,
normal developmental changes, 71
parietal regions, 67
prefrontal cortex, 67
schizophrenia, 40
working memory, 67
schizophrenia, 33, 40
structural neuroimaging, 68–71
amygdala, 69
anterior cingulate cortex, 70,
bilateral cingulate grey matter, 70
bipolar affective disorder, 68
cortical folding patterns, 68,
disease areas of overlap, 69
genetic associations, 70
grey matter density, 68
hippocampus, 69
hypothalamic–pituitary–adrenal axis, 69
longitudinal studies, 69
medial temporal structures, 69
neocortical surface, 71
paracingulate sulcus, 70
pituitary size, 69
prefrontal cortex, 71
regions of interest, 68
schizophrenia, 68
twin studies, 68
UHR, 69
voxel-based morphometry, 68
neuroleptic treatment, DUP outcome effects
use, 129
withheld, 129
neuropathology, schizophrenia, 39
neuropsychological assessment, see FEP assessment
neuropsychological studies, 63–5,
attentional defects, 65
birth cohort studies, 63
as endophenotype, 38
longitudinal studies, 65
long-term studies, 63
olfactory identification, 65
performance IQ, 64
progressive deficits, 65
spatial working memory, 64
story recall tasks, 65
tests, 64
verbal memory deficits, 65
visual reproduction, 65
working memory, 65
see also specific studies
'neurotoxic' effects, DUP, 161
neurotropin 3 4–5 see brain-derived neurotrophic factor
(neurotropin 3)
New York High-Risk Study, 63
NMDA receptor, 35
non-affective psychosis
atypical antipsychotic drugs, 189
pharmacotherapy, 189, 190
non-genetic insults, 70
non-psychotic disorders, PACE UHR criteria, 87
non-psychotic state, suicidal behaviours, 258–9,
Norfolk early intervention service programme
(UK), 343–5
CBT, 344
social recovery aims, 344
Nottingham Onset Schedule, DUP measurement, 130
NRG1 gene/protein see neuregulin
obesity, antipsychotic medication, 188, 195
offset definition, 127
olanzepine, 194
clinical trial, 98
treatment-resistant major depressive
disorder, 375
olfactory identification
at-risk mental state, 95
neuropsychological studies, 65
onset definition, 127
OPUS, 398–400, 401
assertive community treatment, 399–400
ICD-10 schizophrenia diagnosis, 398
psychoeducational family interventions, 400
psychopharmacological therapy, 400
referral to, 399
service model, 399–400
social skills training, 400
treatment evaluation, 400
ORYGEN Research Centre, EPPIC, 388
ORYGEN Youth Health, PACE UHR criteria, 87
Outreach and Support in South London (OASIS), LEO
Service, 389
outreach team LEO Service, 389, 390
P300 abnormality, DUP, 66
P300 event-related potential, psychophysiological
studies, 66
PACE (Personal Assessment and Crisis Evaluation Clinic), 115, 385
at-risk mental state criteria, 107
UHR criteria, 85–8
attenuated psychotic symptoms group, 86
brief limited intermittent psychotic symptoms group, 86
non-psychotic disorders, 87
operation, 86
primary symptom-based, 86
sequential screening, 86
trait and state risk factor group, 86
PACT (Program of Assertive Community Treatment)
Clubhouse model vs., 336
PANSS (Positive and Negative Syndrome Scale for Schizophrenia), 189, 212
relapse definitions, 350
paracingulate sulcus, structural neuroimaging studies, 70
paranoia, at-risk mental state, 114
parietal regions, functional neuroimaging, 67
participant numbers, DUP outcome effects, 136
paternal age, environmental risk factors, 50, 53
patient conflicts, expressed emotion, 311
patient stressors, expressed emotion, 307
perception disturbance, SPI-A, 91
perceptual abnormalities, at-risk mental state, 93
performance IQ, neuropsychological studies, 64
performance measurement, CEPTS, 398, persecutory delusions see delusions
Personal Assessment and Crisis Evaluation Clinic see PACE
personal circumstances, treatment delay, 166–7
personal context recognition, FEP, 178
personal history see FEP assessment
personality traits
FEP, substance misuse, 246
psychosis, course of, 355
relapse, 355
pharmacology
early recovery phase see early recovery phase; medication;
specific disorders
phase-specific group treatment, early recovery phase, 206
phenotypes, intermediate see endophenotypes
physical treatments, suicide prevention, 273
pituitary gland
at-risk mental state, 97
structural neuroimaging, 69
placement, individual, vocational interventions, 338–9,
pleasurable experiences, psychosis, 111
poor functioning, at-risk mental state, 94–5
population-based association studies, 34
population screening, prodrome, 92
Positive and Negative Syndrome Scale for Schizophrenia see PANSS (Positive and Negative Syndrome Scale for Schizophrenia)
positive psychotic phenomena, at-risk mental state, 93
positron emission tomography, FEPP, 395
postpsychotic depression, 286
PPP3CC gene/protein, 32, 38
predictive validity, expressed emotion see expressed emotion
preexisting cognitive problems, EPPIC, 387
prefrontal cortex
functional neuroimaging, 67
structural neuroimaging, 71
premorbid adjustments
DUP follow-up studies, 136–8, 139
relapse, 355
premorbid functioning
FEP, 180
FEP, substance misuse, 244
pre-psychosis onset, treatment, seeking of, 162
prevalence (of psychosis), 3
preventative intervention, 17
Prevention and Early Intervention Program Canada, treatment delay, 164, 165
Prevention and Early Intervention Program for Psychoses (PEPP), 164, 169,
Prevention through Risk Identification, Management and Education see PRIME (Prevention through Risk Identification Management and Education) study
primary care physicians see general practitioners
primary health care
treatment, seeking of, 163–4
treatment delay reduction, 169, 171
primary help seeking, general practitioners, 163,
PRIME (Prevention through Risk Identification Management and Education) study, 109–10, 115
CBT, 115
Criteria for Prodromal Symptoms, 109
FEPP, 392, 395
Global Assessment of Functioning scale, 109
PACE UHR criteria, 87
SOPS scores, 109
SIPS, 87, 109
supportive therapy, 115
PRODH2 gene/protein, 32, 38
prodrome phase, 83–4
attenuated symptoms, 83
‘basic symptoms,’ 83, 98–100
Index

bipolar disorders, 230–1
common symptoms, 84
emotional and personality dysfunctions 284–5
identification drawbacks, 92–3
neurobiological changes, 84
neurocognitive abnormalities, 84
non-specific features, 85
suicide, 260, 261
symptoms and signs, 83
FEP, 180
thoughts, 98, 99
visual perception disturbance, 99
professional contact to treatment delay, DUP, 161, 164–5
professional help, public encouragement of, 149
Program of Assertive Community Treatment see PACT
progressive deficits, neuropsychological studies, 65
protective factors, suicide risk factors, 269
protocols, suicide prevention, 275
psychiatric emergencies, pharmacotherapy, 188, 191
psychiatric management, CEPTS, 396
psychiatrists, public, beliefs about, 149
psychobiological assessments, FEP, 180–5
psychoeducation
at-risk mental state management, 118
bipolar disorders, 234
eye early recovery phase, 204
family interventions see family interventions
FEP, substance misuse, 251–2
relapse prevention, 359
treatment-resistant bipolar disorder, 376
see also public knowledge/beliefs
psychological adjustments, incomplete recovery, 212
Psychological Assistance Service (PAS) (Newcastle), transition rates, 87
psychological interventions
management at-risk mental state, 111–13
evidence 111–13,
bipolar disorders see bipolar disorders
public, beliefs about, 150, 151
relapse prevention, 357
suicide prevention, 273–4
psychological reactions, emotional and personality dysfunctions, 289–91
psychometric psychosis liability, environmental risk factors, 49–50
psychopathological variables, see at-risk mental state
psychopharmacological therapy, OPUS, 400
psychophysiological studies, 65–6
auditoryP50 inhibition deficits, 66
longitudinal studies, 66
mismatch negativity, 66
P300 event-related potential, 66
psychosis
affective see affective psychosis
bipolar disorders, 225
cognitive analytic therapy, 296–7
emotional and personality dysfunction interactions see emotional and personality dysfunctions
expense of, 333
fear of, 112
first episode see FEP
incidence
EPPIC, 386
LEO Service, 389
non-affective see non-affective psychosis
pleasurable experiences, 111
recognition, 178
stage definitions, 20
stigma of, 112
symptoms, borderline personality disorder, 294
psychosocial therapy
early recovery phase see early recovery phase
FEP, incomplete recovery, 215–16
suicide prevention, 274
treatment-resistant bipolar disorder, 376
psychotherapy, individual see individual psychotherapy
public knowledge/beliefs, 147–50
first aid skills, 148–9
of professionals, 149, 150
professionals vs., 151–3,
recognition of psychosis, 147–8,
schizophrenia/split personality association, 149
treatments, 150
see also psychoeducation
public education
treatment delay reduction, 168, 170
see also psychoeducation
publicly funded health care loss, employment barriers, 332
qualifications/experience, employment barriers, 332
quality of life, early recovery phase, 208
quality of life scale, early recovery phase, 208
quantitative data analysis, DUP follow-up studies, 133
quetiapine, 194
treatment-resistant major depressive disorder, 375

© Cambridge University Press www.cambridge.org
randomized controlled trials
CBT, 205
FEP, substance misuse, 247,
see also specific trials
RAP see Hillside Recognition and Prevention Program
rapid cycling bipolar disorders, 374
treatment resistance, 374, 375–7
rate of transition, relapse rates, 351
realization of illness, suicidal behaviours, 262
rearing environment measures, gene–environment
interactions, 49
receptive language disturbance, prodrome basic symptoms, 99
recovery phase, suicide see suicide
cognitive deficits, 355–6
definition/assessment, 350–1
expression, 306
personality adjustment, 355
prediction see below
premorbid adjustment, 355
prevention see below
rates of, 351
suicide, 261, 263
relapse prediction/prevention, 14, 349–64,
antipsychotic medication, 356–7
bipolar disorders, 235
CBT 360
clinical trial, 97
maintenance medication, relapse, 357
treatment-resistant major depressive disorder, 375
routine risk monitoring, suicide prevention, 269–72
Royal Park Multidiagnostic Instrument for Psychosis
(RP-MIP), DUP measurement, 128, 132
safety behaviours, emotional and personality dysfunctions, 287
sample size, gene–environment interactions, 56
Scale of Prodromal Symptoms see SOPS
schizoaffective disorder, treatment resistance
definition, 365–6
non-pharmacological management, 375–6
pharmacological management, 371–3
prevalence, 367
schizophrenia
chromosomal translocations, 36
environmental effects, 40
functional neuroimaging, 40
illicit drug use, 40
neurodevelopmental hypothesis, 39
neuroimaging, 33, 40
neuropathology, 39
phenotype, 32–3
split personality association, 149
structural neuroimaging, 68
suicide risk factors, 263
treatment resistance, 365
definition, 365–6
non-pharmacological management, 375–6
pharmacological management, 371–3
prevalence, 367
Schizophrenia Patient Outcomes Research Team (PORT),
relapse-prevention treatment guidelines, 349
Recovery in Schizophrenia Working Group, 370
repetitive transcranial magnetic stimulation
treatment-resistant major depressive disorder, 376, 377
treatment-resistant schizophrenia, 376
resistance to treatment see treatment resistance
retrospective data, DUP onset, 127
reviews, suicide risk monitoring, 269
RGS4 (regulator of G-protein signalling-4), 32, 35–6
risk assessments
FEP, 179, 181, 183–4
suicide prevention see suicide prevention
risperidone, 194
adverse effects, 110
at-risk mental state management, 108
clinical trial, 97
maintenance medication, relapse, 357
treatment-resistant major depressive disorder, 375
Royal Park Multidiagnostic Instrument for Psychosis
(RP-MIP), DUP measurement, 128, 132
safety behaviours, emotional and personality dysfunctions, 287
sample size, gene–environment interactions, 56
Scale of Prodromal Symptoms see SOPS
schizoaffective disorder, treatment resistance
definition, 365–6
non-pharmacological management, 375–6
pharmacological management, 371–3
prevalence, 367
schizophrenia
chromosomal translocations, 36
environmental effects, 40
functional neuroimaging, 40
illicit drug use, 40
neurodevelopmental hypothesis, 39
neuroimaging, 33, 40
neuropathology, 39
phenotype, 32–3
split personality association, 149
structural neuroimaging, 68
suicide risk factors, 263
treatment resistance, 365
definition, 365–6
non-pharmacological management, 375–6
pharmacological management, 371–3
prevalence, 367
Schizophrenia Patient Outcomes Research Team (PORT),
relapse-prevention treatment guidelines, 349
Remission in Schizophrenia Working Group, 370
repetitive transcranial magnetic stimulation
treatment-resistant major depressive disorder, 376, 377
treatment-resistant schizophrenia, 376
resistance to treatment see treatment resistance
retrospective data, DUP onset, 127
reviews, suicide risk monitoring, 269
RGS4 (regulator of G-protein signalling-4), 32, 35–6
risk assessments
FEP, 179, 181, 183–4
suicide prevention see suicide prevention
risperidone, 194
adverse effects, 110
at-risk mental state management, 108
clinical trial, 97
maintenance medication, relapse, 357
treatment-resistant major depressive disorder, 375
Royal Park Multidiagnostic Instrument for Psychosis
(RP-MIP), DUP measurement, 128, 132
safety behaviours, emotional and personality dysfunctions, 287
sample size, gene–environment interactions, 56
Scale of Prodromal Symptoms see SOPS
schizoaffective disorder, treatment resistance
definition, 365–6
non-pharmacological management, 375–6
pharmacological management, 371–3
prevalence, 367
schizophrenia
chromosomal translocations, 36
environmental effects, 40
functional neuroimaging, 40
illicit drug use, 40
neurodevelopmental hypothesis, 39
neuroimaging, 33, 40
neuropathology, 39
phenotype, 32–3
split personality association, 149
structural neuroimaging, 68
suicide risk factors, 263
treatment resistance, 365
definition, 365–6
non-pharmacological management, 375–6
pharmacological management, 371–3
prevalence, 367
Schizophrenia Patient Outcomes Research Team (PORT),
relapse-prevention treatment guidelines, 349
schizotypal personality features, at-risk mental state, 93
school-based programmes, mental health literacy, 155–7
SoCRATES trial, CBT, 205
screening, sequential, PACE UHR criteria, 86
search strategies, DUP follow-up studies, 130
secondary prevention, relapse prevention, 359
second-generation antipsychotic see antipsychotic medication
second generation studies, gene–environment interactions, 54–5
selective serotonin-reuptake inhibitors (SSRIs), suicidal
treatment, 273
self-experiencing disturbances, SPI-A, 91
self-focus attention, 290
self-harm, 260
self-help, suicide prevention, 274–5
self-medication hypothesis, FEP, substance misuse, 245
self-preservation, suicidal behaviours, 260
sensitivity analysis, DUP follow-up studies, 138–9, 140–1
sensory gating, at-risk mental state, 96
sequential screening, PACE UHR criteria, 86
serotonin breakdown product and suicide risk, 266
selective serotonin-reuptake inhibitors, suicidal behaviour
treatment, 273
services
Factors
FEP, 216
incomplete recovery, 216
suicide risk, 268–9
reviews, suicide prevention, 275
social services
suicide prevention, 276
treatment delay reduction, 169
see also specific service models
sexual side effects, antipsychotic medication, 189, 195–6
shame, emotional and personality dysfunctions, 289–90
shared developmental pathways, emotional and personality
dysfunctions, 288–9, 290
single nucleotide polymorphisms
allele association studies, 34
DAOA, 35
SIPS (Structured Interview for Prodromal Symptoms), PRIME
study, 87, 109
sleep disturbances, at-risk mental state, 114
smoking, FEP, 243, 244, 245, 248
social anxiety, 286
cognitive models, 290–1,
emotional and personality dysfunctions, 289–90
social assessment, FEP, 181
social contexts, expressed emotion, 311
social deficits, incomplete recovery, 208–9
social factors, suicide risk factors, 267–8
social firms, 334–5
disadvantages, 335
Italy, 335
supported employment vs., 338
UK, 335
Social Functioning Scale, treatment delays, 168
social groups, suicide prevalence, 267
social interventions, at-risk mental state management, 113
social networks, treatment delays, 166
Social Phobia and Anxiety Inventory, 208
social policies, suicide prevention, 276
social problems
at-risk mental state, 125–45
withdrawal, 114
social recovery aims, Norfolk Early Intervention Service, 344
social services see services; social services
social skills training, OPUS, 400
socioeconomic status, treatment delays, 166
SOPS (Scale of Prodromal Symptoms) scores
scores in PRIME study, 109
Soteria Project, maintenance medication, 353
spatial working memory, neuropsychological studies, 64
SPI-A (Schizophrenia Proneness Instrument, Adult Version), 91–2
affective–dynamic disturbances, 91
body perception disturbance, 91
cognitive–attentional impediments, 91
cognitive disturbances, 91
perception disturbance, 91
self-experiencing disturbances, 91
staff awareness, suicide prevention, 275
staging models, 3–4, 17–27, 31
family interventions, 316–20
as heuristic model, 22
neurodevelopmental framework, 20
progress in, 18
stage 0, 21
stage 1a, 21, 23–4,
stage 1b, 21, 23–4,
stage 2 see FEP
stage 3a, 21, 23, 24
stage 3b, 21, 23
stage 3c, 22, 23
stage 4, 22, 23
standardized assessment instruments, DUP, 128–9
stepped-care, FEP, substance misuse, 249
stigma
emotional and personality dysfunctions, 289–90
psychosis, 112
story recall tasks, neuropsychological studies, 65
stress
at-risk mental state, 95
and coping paradigms, family caregiving, 315
relapse predictors/risk factors, 354
stressful life events, suicide risk factors, 267
‘Stress Management’ module, at-risk mental state
management, 108
structural neuroimaging see neuroimaging, structural
Structured Interview for Prodromal Symptoms see SIPS
studies
DUP follow-up studies, 18–19, 130, 133, 134–5
longitudinal see longitudinal studies
long-term, 63
substance abuse/misuse, 11, 243–56
at-risk mental state, 95
bipolar disorder, 225, 234
CEPTS, 397
EPPIC, 389
FEP, 183
prevalence, 11
relapse predictors/risk factors, 354
schizophrenia, 40
suicide risk, 266
treatment delays, 168
see also specific drugs/substances
substance use disorder, incomplete recovery, FEP, 211
Suffolk County study, DUP, 142
suicidal behaviours, 258–60, 270
depression, 261
FEP, substance misuse, 245
fluctuating course of, 261, 262, 268
non-psychotic state, 258–9
and section, 259–60, 261
realization of illness, 262
suicide prevention, 272
suicide
EPPIC, 388
factors, 258
FEP, 183, 260
first-episode acute phase, 260–2
incidence, 257
methods chosen, 260
pre-illness, 261
prevalence
between countries, 267, 268
ethnicity, 267
social groups, 267
prevention see suicide prevention
prodrome phase, 260, 261
recovery phase, 261, 262
support withdrawal, 262
relapse phase, 261, 263
risk-assessment schedules, 265
risk factors
cultural factors, 267–8
family factors, 267–8
family history of, 267
protective factors, 269
schizophrenia, 263
service factors, 268–9
social factors, 267–8
stressful life events, 267
treatment factors, 268–9
wider effects of, 258
Suicide Intervention Project, 157
suicide prevention, 11–12, 257–81
biological risk markers, 266–7
early intervention effects, 258
future work, 276–7
indicated interventions, 272–5
acute risk containment, 272–3
pharmacological interventions, 273
physical treatments, 273
psychological interventions, 273–4
psychosocial interventions, 274
self-help, 274–5
suicidal factors, 272
Initial Suicide Risk Assessment and Formulation, 265–6,
networks, 268
risk assessments, 263–9,
critical questions, 264
previous attempts, 264
triggering events, 264
see also specific types
risk management, 269–76
selective interventions, 258–60, 269–72,
routine risk monitoring, 269–72
suicide risk assessment schedules, 265
universal interventions, 269, 275–6
debriefing, 275
mental health service provision models, 275–6
protocols, 275
service reviews, 275
social policies, 276
social services, 276
staff awareness, 275
training provision, 275
supported employment, 338
clubhouse model vs., 338
social firms vs., 338
see also individual placement and support approach
supportive interventions
family interventions, 321–2
PRIME study, 115
Survival Skills Workshop, OPUS, 400
susceptibility genes, 31, 32
suspiciousness, at-risk mental state, 114
symptomatic remission, bipolar disorders, 225
Symptom Onset in Schizophrenia Inventory (SOS), DUP measurement, 130
symptoms
FEP, substance misuse, 244
inconsistency, DUP onset, 126
symptom to professional contact delay, DUP, 161
syndromal remission, bipolar disorders, 224
Systematic Treatment of Persistent Psychosis (STOPP), incomplete recovery therapy, 216
tardive dyskinesia
antipsychotic medication, 188, 194–5, 228
bipolar disorder, 228
targeted medication regimens, relapse prevention, 360
Texas Medication Algorithm Program, 215
thoughts in prodromal basic symptoms
blockage, 99
interference, 98
perseveration, 98
pressure, 98
timing
relapse prediction/prevention, 358
relapse prevention, 358
tobacco use, FEP, 243, 244, 245, 248
TOPP Clinic (Norway), transition rates, 87
training programmes, mental health literacy, 157
training provision, suicide prevention, 275
tranzquilization, psychiatric emergencies, 193
transitional employment, clubhouse model, 335
traumatic reactions, emotional and personality dysfunctions, 289
TREAT (Treatment Resistance Early Assessment Team) programme
EPPIC, 387,
incomplete recovery, 214
suicide risk, 271
treatment, seeking of, 162–6, 170
barriers to, 164
facilitation variation, 165, 170
family actions, 163, 170
non-psychosis symptoms, 162
pre-psychosis onset, 162
primary health care advisors, 163–4
treatment adherence, FEP treatment, 184, 188, 195
Treatment and Intervention in Psychosis (TIPS) study, 153, 169,
DUP, 125
success of, 170
treatment delay
access problems, 165–6
aspects of illness onset, 167–8
family history of psychosis, 168
functioning levels, 167
suddenness effects, 167
bipolar disorders see bipolar disorders
clinician errors, 171
demography/personal circumstances, 166–7
prediction of, 166–8
substance abuse, 168
treatment delay reduction, 8–9, 161–74,
antipsychotic drug response, 185
community efforts, 168
FEP treatment, 185
primary health care, 169, 171
public education, 168, 170
social service providers, 169
treatment evaluation, OPUS, 400
treatment resistance, 14, 365–81
definitions, 365
early detection, 370–1
from treatment initiation, 370
factors, 378
FEP treatment, 202, 214
incidence, 365
major depressive disorder see major depressive disorder,
treatment resistance
management, 368–77
clinical effectiveness definitions, 370
intervention optimization, 368–70
non-pharmacological, 374, 375–7
pharmacological adaptations, 371–5,
prediction strategies, 370
service prerequisites, 368–70
treatment resistance (cont.)
mood cycling, 366
predictors, 368, 369
prevalence, 367–8, 378
schizoaffective disorder see schizoaffective disorder, treatment resistance
symptoms, 366
Treatment Resistance Early Assessment Team see TREAT
treatment-resistant depression, 366
trigging hallucinations, emotional and personality dysfunctions, 288
twin studies
environmental risk factors, 49
first-generation studies, 51, 52
structural neuroimaging, 68
UCLA (University of California at Los Angeles) Aftercare Research Program, 342–3
brokered model vs., 343
comparison group, 343
Developmental Processes in Schizophrenic Disorders Project, 342
employment specialists, 342
full implementation, 342
Workplace Fundamentals Module, 342, UCLA (ultra-high risk), 63
expressed emotion, 307–8, 309–10
intervention, 97–8
cognitive therapy, 97
supportive therapy vs., 97, 98
structural neuroimaging, 69
supportive therapy, intervention vs., 97, 98
see also at-risk mental state
ultra-high risk, see UHR
unemployment, effects of, 332–4
unfavourable outcome identification, FEP treatment, 189, 195–6
United Kingdom (UK)
school-based mental health literacy, 156
social firms, 335
see also specific schemes
universal interventions, suicide prevention see suicide prevention
unstable ideas of reference, prodrome basic symptoms, 99
vagus nerve stimulation, treatment-resistant major depressive disorder, 376
Val158Met genotype, COMT gene, 36, 55
validity assessment, DUP follow-up studies, 132
velo-cardial facial syndrome, 36
verbal memory deficits, neuropsychological studies, 65
victimization, FEP, 183
violence, FEP, 183
visual perception disturbances, prodrome basic symptoms, 99
visual reproduction, neuropsychological studies, 65
vocational functioning see work functioning
vocational interventions, 334–9
case study, 341
EPPIC, 340–1
FEP, 339–45
incomplete recovery, 212, 216
individual placement, 338–9
industrial therapy, 334
job agencies, 341
LEO Service, 390
see also clubhouse model, Norfolk Early Intervention Service, social firms, UCLA Aftercare Research Program
voxel-based morphometry, structural neuroimaging, 68
vulnerability–stress–coping model, FEP, 179
weight gain, antipsychotic medication, 188, 195
work functioning, 13–14, 335
early recovery phase, 206–7
employment barriers, 332
employment rates, 333
historical aspects, 331
incomplete recovery therapy, 212, 216
interventions see vocational interventions
positive benefits, 334
type of work, 332
working memory
at-risk mental state, 95
endophenotypes, 72
functional neuroimaging, 67
neuropsychological studies, 65
Workplace Fundamentals Module, UCLA Aftercare Research Program, 342,
youth participation, EPPIC, 388
ziprasidone, 194
treatment-resistant major depressive disorder, 375
zotepine, 194,